Cognition Therapeutics
CGTX · Nasdaq · United States
Share price · CGTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when CGTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 15 Oct 2026-5.7%
Nothing announced by CGTX that day or the session before.
- 24 Jun 2026-38.2%
- 1 Apr 2026+17.4%
Nothing announced by CGTX that day or the session before.
- 31 Mar 2026+27.7%
Nothing announced by CGTX that day or the session before.
- 30 Mar 2026-18.6%
Nothing announced by CGTX that day or the session before.
- 27 Mar 2026-32.4%
- 30 Jan 2026-12.1%
Nothing announced by CGTX that day or the session before.
- 23 Dec 2025-11.9%
Nothing announced by CGTX that day or the session before.
Share of unusual movement by asset
For each asset, the share of CGTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | Sigma-2 receptor complexSmall molecule | Alzheimer's DiseaseDementia with Lewy Bodies |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
May 2027 (1)
What to watch
Regulatory and conference events
(2)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $5.1M | $31M | $4.1M-$3.3M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $5.1M | $35M | $3.9M-$3.0M operating cash flow | report ↗ |
| 2026-Q1 | — | $6.1M | $31M | $4.6M-$5.5M operating cash flow | report ↗ |
| 2025-Q3 | — | $3.8M | $40M | $4.9M-$5.7M operating cash flow | report ↗ |
| 2025-Q2 | — | $11M | $12M | $6.7M-$5.6M operating cash flow | report ↗ |
| 2025-Q1 | — | $11M | $16M | $8.5M-$9.9M operating cash flow | report ↗ |
| 2024-Q3 | — | $11M | $22M | $9.9M-$6.8M operating cash flow | report ↗ |
| 2024-Q2 | — | $12M | $29M | $7.0M-$6.0M operating cash flow | report ↗ |
| 2024-Q1 | — | $11M | $35M | $9.2M-$7.2M operating cash flow | report ↗ |
| 2023-Q3 | — | $12M | $33M | $6.8M-$4.2M operating cash flow | report ↗ |
| 2023-Q2 | — | $8.5M | $37M | $4.7M-$3.7M operating cash flow | report ↗ |
| 2023-Q1 | — | $5.4M | $39M | $6.2M-$2.7M operating cash flow | report ↗ |
| 2022-Q3 | — | $8.3M | $47M | $6.6M$0 operating cash flow | report ↗ |
| 2022-Q2 | — | $9.1M | $46M | $5.8M-$5.4M operating cash flow | report ↗ |
| 2022-Q1 | — | $6.5M | $52M | $3.8M-$3.0M operating cash flow | report ↗ |
| 2021-Q3 | — | $3.7M | $8.3M | $3.1M-$2.0M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $37M | $37M | $5.9M-$25M operating cash flow | report ↗ |
Cognition Therapeutics reported no revenue for fiscal year 2025, with R&D spend of $37.19M, down 10.8% YoY. Cash and equivalents stood at $37M, and the company reported a net loss of $23.49M. No analyst consensus figures were provided.
The company is advancing zervimesine for DLB psychosis, with an FDA Division of Psychiatry meeting expected by mid-2026, and has completed enrollment in the Phase 2 START trial in early Alzheimer's disease, with topline results expected in 2027. Management estimates sufficient cash to fund operations through the second quarter of 2027.
Insider transactions
Open-market activity, trailing 12 months: 3 purchases ($32K), 0 sales ($0). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-06-17 | Fletcher Aaron G.L.; BIOS Capital Management, LP; BIOS Advisors GP, LLC; Bios Equity Partners, LP; BIOS Fund I, LP; BIOS Fund II QP, LP; BIOS Memory SPV I, LP; Bios Equity Partners II, LP; BIOS Fund II, LP; BIOS Fund I QP, LP · director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner; director, 10% owner | Award / grant | 25,000 | — | — | Form 4 |
| 2026-06-17 | RICHSTONE ELLEN B · director | Award / grant | 25,000 | — | — | Form 4 |
| 2026-06-17 | Wallace Peggy · director | Award / grant | 25,000 | — | — | Form 4 |
| 2026-06-17 | Monia Brett P · director | Award / grant | 25,000 | — | — | Form 4 |
| 2026-06-17 | Khattar Jack A. · director | Award / grant | 25,000 | — | — | Form 4 |
| 2026-05-01 | Doyle John Brendan · Chief Financial Officer | Tax withholding | 8,567 | $1.28 | $11K | Form 4 |
| 2026-04-16 | Caggiano Anthony · Chief Medical Officer | Open-market purchase | 10,000 | $1.11 | $11K | Form 4 |
| 2026-04-16 | Ricciardi Lisa · director, CEO & President | Open-market purchase | 9,175 | $1.10 | $10K | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 75 reporting institutions held 21.4M shares ($16.1M, 22.5% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BIOS Capital Management, LP | 6,000,000 | $4.6M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 3,001,787 | $2.3M |
| 3 | DAVENPORT & Co LLC | 2,892,808 | $2.2M |
| 4 | RENAISSANCE TECHNOLOGIES LLC | 1,117,136 | $848K |
| 5 | Chescapmanager LLC | 997,029 | $757K |
| 6 | BlackRock, Inc. | 968,362 | $735K |
| 7 | GEODE CAPITAL MANAGEMENT, LLC | 920,208 | $699K |
| 8 | Hilton Capital Management, LLC | 548,950 | $417K |
| 9 | VANGUARD FIDUCIARY TRUST CO | 463,684 | $352K |
| 10 | Dauntless Investment Group, LLC | 431,000 | $327K |
| 11 | CM Management, LLC | 400,000 | $304K |
| 12 | JANE STREET GROUP, LLC | 370,140 | $281K |
| 13 | Sigma Planning Corp | 337,765 | $257K |
| 14 | STATE STREET CORP | 314,483 | $239K |
| 15 | AMERICAN FINANCIAL GROUP INC | 205,000 | $156K |